

SCHEDULE 14A INFORMATION  
Proxy Statement Pursuant to Section 14(a) of the Securities  
Exchange Act of 1934 (Amendment No. )

Filed by the Registrant  [X]  
Filed by a Party other than the Registrant  [ ]

Check the appropriate box:

[X] Preliminary Proxy Statement  [ ] Confidential, for Use of the  
Commission Only (as permitted by  
Rule 14a-6(e)(2))

[ ] Definitive Proxy Statement  
 [ ] Definitive Additional Materials  
 [ ] Soliciting Material Under Rule 14a-12

Haemonetics Corporation

-----  
(Name of Registrant as Specified In Its Charter)

-----  
(Name of Person(s) Filing Proxy Statement, if Other Than Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.  
 [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

-----  
2) Aggregate number of securities to which transaction applies:

-----  
3) Per unit price or other underlying value of transaction computed  
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the  
filing fee is calculated and state how it was determined):

-----  
4) Proposed maximum aggregate value of transaction:

-----  
5) Total fee paid:

-----  
 [ ] Fee paid previously with preliminary materials:

-----  
 [ ] Check box if any part of the fee is offset as provided by Exchange  
Act Rule 0-11(a)(2) and identify the filing for which the offsetting  
fee was paid previously. Identify the previous filing by registration  
statement number, or the Form or Schedule and the date of its filing.

1) Amount previously paid:

-----  
2) Form, Schedule or Registration Statement No.:

-----  
3) Filing Party:

-----  
4) Date Filed:

-----  
HAEMONETICS CORPORATION  
Notice of Special Meeting of Stockholders  
December 14, 2000

To the Stockholders:

A Special Meeting of the Stockholders of Haemonetics Corporation will  
be held on Thursday, December 14, 2000 at 9:00 a.m. at the offices of  
Haemonetics Corporation, 400 Wood Road, Braintree, Massachusetts for the  
following purposes.

1. To consider and act upon a proposal to approve the Haemonetics  
Corporation 2000 Long-Term Incentive Plan.
2. To consider and act upon any other business which may properly  
come before the meeting.

The Board of Directors has fixed the close of business on October 27,  
2000 as the record date for the meeting. All stockholders of record on that  
date are entitled to notice of and to vote at the meeting.

PLEASE COMPLETE AND RETURN THE ENCLOSED PROXY IN THE ENVELOPE PROVIDED  
WHETHER OR NOT YOU INTEND TO BE PRESENT AT THE MEETING IN PERSON.

By Order of the Board of Directors

Alicia R. Lopez, Clerk

Braintree, Massachusetts  
November 13, 2000

HAEMONETICS CORPORATION

PROXY STATEMENT

This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors of Haemonetics Corporation (the "Company") for use at the Special Meeting of Stockholders to be held on Thursday, December 14, 2000, at the time and place set forth in the notice of meeting, and at any adjournment thereof. The approximate date on which this Proxy Statement and form of proxy are first being sent to stockholders is November 13, 2000.

If the enclosed proxy is properly executed and returned, it will be voted in the manner directed by the stockholder. If no instructions are specified with respect to any particular matter to be acted upon, the proxy will be voted in favor thereof. Any person giving the enclosed form of proxy has the power to revoke it by voting in person at the meeting or by giving written notice of revocation to the Clerk of the Company at any time before the proxy is exercised.

The holders of a majority in interest of all Common Stock issued, outstanding and entitled to vote are required to be present in person or be represented by proxy at the Meeting in order to constitute a quorum for transaction of business. The affirmative vote of the holders of at least a majority of the shares of Common Stock voting thereon in person or by proxy at the meeting is required to approve item 1 listed in the notice of meeting. Abstentions are counted as present in determining whether the quorum requirement is satisfied. Abstentions will be counted in the tabulation of votes cast on Item 1.

The Company will bear the cost of this solicitation. It is expected that the solicitation will be made primarily by mail, but regular employees or representatives of the Company (none of whom will receive any extra compensation for their activities) may also solicit proxies by telephone, telegraph or in person and arrange for brokerage houses and their custodians, nominees and fiduciaries to send proxies and proxy materials to their principals at the expense of the Company. The Company may retain a proxy solicitation firm to aid in soliciting proxies from its stockholders. The fees of any such firm are not expected to exceed \$5,000 plus reimbursement of out-of-pocket expenses.

The Company's principal executive offices are located at 400 Wood Road, Braintree, Massachusetts 02184-9114, telephone number (781) 848-7100.

RECORD DATE AND VOTING SECURITIES

Only stockholders of record at the close of business on October 27, 2000 are entitled to notice of and to vote at the meeting. On that date, the Company had outstanding and entitled to vote [ ] shares of Common Stock with a par value of \$.01 per share. Each outstanding share entitles the record holder to one vote.

APPROVAL OF 2000 LONG-TERM INCENTIVE PLAN

There will be presented at the meeting a proposal to approve the Haemonetics Corporation 2000 Long-Term Incentive Plan (the "Plan"), which was adopted by the Board of Directors on October 24, 2000. The Board of Directors recommends that the stockholders approve the Plan. Set forth below is a summary of the principal provisions of the Plan, a copy of which may be obtained from the Clerk of the Company upon request.

This Plan replaces the Haemonetics Corporation 2000 Long-Term Incentive Plan (the "May Plan") which was adopted by the Board of Directors on May 2, 2000 and originally scheduled to be considered by the stockholders at the Annual Meeting held July 25, 2000. The May Plan was not acted upon at the Annual Meeting because the Company determined that changes in the plan would be required in order to secure stockholder approval. No options were granted under the May Plan. The revised plan adopted by the Board of Directors on October 24, 2000 (i) reduces the maximum number of shares available for the grant of options to 4,000,000 from 6,000,000, (ii) eliminates a feature contained in the May Plan which provided for automatic increases in the number of shares available for issuance under the May Plan based upon the number of issued and outstanding shares of the Company's Common Stock, (iii) eliminates the issuance of stock awards and (iv) requires that the exercise price for options granted under the Plan must be not less than the fair market value of the Company's Common Stock at the time the option is granted. The new Plan also provides that except for adjustments for recapitalizations, reorganizations, and certain other corporate transactions, the exercise price for any outstanding option granted under the Plan may not be decreased after the date of grant, nor

may an outstanding option be surrendered to the Company as consideration for the grant of a new option with a lower exercise price.

The Company believes that it is in the best interests of its stockholders to adopt incentive compensation programs which align the interests of key employees with those of the stockholders. The Company's 1992 Long-Term Incentive Plan will terminate in August, 2002. The Company's 1990 Stock Option Plan terminated March 30, 2000. Accordingly, the Company believes it is necessary to adopt the Plan so that the Company will be able to continue to offer an incentive compensation program which will be attractive to current and prospective key employees. Upon approval of the Plan by the stockholders, no further options will be granted under the 1992 Long-Term Incentive Plan or under the Company's 1998 Stock Option Plan for Non-Employee Directors. Options granted under both plans will continue to remain outstanding under the terms thereof.

**Purpose.** The Plan is intended to promote the interests of the Company and its stockholders by strengthening the Company's ability to attract and retain competent employees and to encourage ownership of the Company's stock by employees, directors, consultants and advisers of the Company and its subsidiaries upon whose efforts and initiative the growth and success of the Company depends. The Plan permits the grant of stock options, which may be either incentive stock options meeting the requirements of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code") or non-qualified options which are not intended to meet the requirements of the Code. Shares issued under the Plan may be authorized but unissued shares of Common Stock or shares of Common Stock held in the Treasury.

**Number of Shares.** The maximum number of shares of the Company's Common Stock available for stock options granted under the Plan is 4,000,000 shares of Common Stock. The maximum number of shares available for grants is subject to adjustment for capital changes.

To the extent that any option lapses, terminates, expires or otherwise is cancelled without the issuance of shares of Common Stock, the shares of Common Stock covered by such grants are again available for the granting of stock options. If any such stock option is exercised through the full or partial payment of shares of Common Stock owned by the optionee, shares equal in number to those tendered by the optionee are added to the maximum number of shares available for future grants under the Plan.

It is not possible to state the employees who will receive stock options under the plan in the future, nor the amount of options which will be granted thereunder. Reference is made to the section entitled "Executive Compensation" in this Proxy Statement for information concerning options granted to and exercised by the named executive officers during the most recent fiscal year and options outstanding at April 1, 2000.

**Administration.** The Plan is administered by the Compensation and Management Development Committee (the "Committee") consisting of two or more members of the Company's Board of Directors. The present members of the Committee are Sir Stuart Burgess, N. Colin Lind, Benjamin L. Holmes, Donna C. E. Williamson, and Ronald G. Gelbman.

**Termination and Amendment.** Unless sooner terminated, the Plan shall terminate ten years from October 24, 2000, the date upon which it was adopted by the Board of Directors. The Board of Directors may at any time terminate the Plan or make such modification or amendment as it deems advisable; provided however that the Board of Directors may not, without the approval of the stockholders of the Company, make any change in the Plan which (i) requires stockholder approval under applicable law or regulations; and (ii) increases the number of shares available for stock options, (iii) expands the class of participants eligible to receive stock option grants under the Plan, or (iv) materially increases benefits under the Plan by expanding the types of permissible awards (such as by authorizing the grant of stock awards or stock appreciation rights). The Committee may terminate, amend or modify any outstanding option without the consent of the option holder, provided however that, without the consent of the optionee, the Committee shall not change the number of shares subject to an option, nor the exercise price thereof, nor extend the term of such option.

**Eligibility to Participate.** The Plan provides that options designated as incentive stock options may be granted only to officers and employees of the Company or any subsidiary corporation. Options designated as non-qualified options may be granted to officers, directors, employees, consultants and advisers of the Company or any of its subsidiaries. In determining a person's eligibility to be granted an option, the Committee takes into account the person's position and responsibilities, the nature and value to the Company or its subsidiaries of such person's service and accomplishments, such person's present and potential contribution to the success of the Company or its subsidiaries, and such other factors as the Committee deems relevant. The maximum number of shares of the Company's Common Stock with respect to which an option may be granted under the Plan to any employee in any one fiscal year of the Company shall not exceed 500,000 shares (in the aggregate for all such options taken together), subject to adjustment for capital changes.

**Terms and Provisions of Options.** Options granted under the Plan are exercisable at such times and during such period as is set forth in the

option agreement, but no incentive stock option granted under the Plan can have a term in excess of ten years from the date of grant. The option agreement may contain such provisions and conditions (including pre-established performance objectives and forfeiture of option gain for competition with the Company) as may be determined by the Committee. The option exercise price for stock options granted under the Plan must be no less than the fair market value of the Company's Common Stock at the time the option is granted. Except for adjustments for recapitalizations, reorganizations, and certain other corporate transactions, the exercise price for any outstanding option granted under the Plan may not be decreased after the date of grant, nor may an outstanding option be surrendered to the Company as consideration for the grant of a new option with a lower exercise price. Options granted under the Plan may provide for the payment of the exercise price by (i) the delivery of cash or a check in an amount equal to the exercise price, (ii) the delivery of certificates of shares of Common Stock of the Company owned by the optionee and acceptable to the Committee having a fair market value equal to the exercise price of the option being exercised, or attestation of beneficial ownership of such shares, (iii) a "cashless exercise" (wherein a third party is authorized to sell shares of Common Stock acquired upon exercise of the option and to remit to the Company a sufficient portion of the sales proceeds to pay the exercise price), (iv) using the proceeds of a recourse loan from the Company to pay the exercise price, or (v) any combination thereof.

Except as provided in the option agreement, the right of any optionee to exercise an option granted under the Plan is not assignable or transferable by such optionee otherwise than by will or the laws of descent and distribution, and any such option shall be exercisable during the lifetime of such optionee only by him or her.

Recapitalizations, Reorganizations, Change in Control. The Plan provides that the number and kind of shares as to which options, may be granted thereunder and as to which outstanding options or portions thereof then unexercised shall be exercisable shall be adjusted to prevent dilution in the event of any reorganization, merger, consolidation, recapitalization, reclassification, stock split-up, combination of shares, spin-off, distribution of assets or dividends payable in capital stock. In addition, unless otherwise determined by the Committee in its sole discretion, in the case of any sale or conveyance to another entity of all or substantially all of the property and assets of the Company or a Change in Control as defined in the Plan, the purchaser of the Company's assets or stock may deliver to the optionee the same kind of consideration that is delivered to the shareholders of the Company as a result of such sale, conveyance or Change in Control or the Committee may cancel all outstanding options in exchange for consideration in cash or in kind, which consideration shall be equal in value to the value of those shares of stock or other securities the optionee would have received had the option been exercised (to the extent then exercisable) and no disposition of the shares acquired upon such exercise has been made prior to such sale, conveyance or Change in Control, less the option price therefor. The Committee may provide in any option agreement that the vesting of any options shall automatically accelerate in full or in part upon such a sale, conveyance or Change in Control.

The Committee shall also have the power to accelerate the exercisability of any options, notwithstanding any limitations in the Plan or in the option agreement, upon such a sale, conveyance or Change in Control. Change in Control is defined in the Plan as having occurred if any person, or any two or more persons acting as a group, and all affiliates of such person or persons, who prior to such time owned less than 35% of the then outstanding Common Stock of the Company, shall acquire such additional shares of the Company's Common Stock in one or more transactions, or series of transactions, such that following such transaction or transactions, such person or group and affiliates beneficially own 35% or more of the Company's Common Stock outstanding.

Upon dissolution or liquidation of the Company, all options granted under the Plan shall terminate, but each optionee shall have the right, immediately prior to such dissolution or liquidation, to exercise his or her options to the extent then exercisable.

In the case of a corporate merger, consolidation, acquisition of property or stock, separation, reorganization, liquidation or other similar transaction to which Section 424(a) of the Code applies, the Committee may grant an option or options upon such terms and conditions as it may deem appropriate for the purpose of assumption of the outstanding options, or substitution of new options for the outstanding option, in conformity with provisions of Section 424(a) of the Code and the regulations thereunder, and any such action shall not reduce the number of shares otherwise available for issuance under the Plan.

The high and low sales prices of the Company's Common Stock on the New York Stock Exchange on October \_\_, 2000 were \$\_\_\_\_\_ and \$\_\_\_\_\_, respectively.

#### TAX EFFECTS OF PLAN PARTICIPATION

Options granted under the Plan are intended to be either incentive stock options, as defined in Section 422 of the Code, or non-qualified stock options.

Incentive Stock Options. Except as provided below with respect to the alternative minimum tax, the optionee will not recognize taxable income upon the grant or exercise of an incentive stock option. If the optionee holds the shares received pursuant to the exercise of the option for at least one year after the date of exercise and for at least two years after the option is granted, the optionee will recognize long-term capital gain or loss upon the disposition of the stock measured by the difference between the option exercise price (the stock's basis) and the amount received for such shares upon disposition.

In the event that the optionee disposes of the stock prior to the expiration of the required holding periods (a "disqualifying disposition"), the optionee generally will realize ordinary income in the year of disposition equal to the difference between the exercise price and the lower of the fair market value of the stock at the date of the option exercise or the sale price of the stock. The basis in the stock acquired upon exercise of the option will equal the amount of income recognized by the optionee plus the option exercise price. Upon eventual disposition of the stock, the optionee will recognize long-term or short-term capital gain or loss, depending on the holding period of the stock and the difference between the amount realized by the optionee upon disposition of the stock and the optionee's basis in the stock.

For alternative minimum tax purposes, the excess of the fair market value of stock on the date of the exercise of the incentive stock option over the exercise price of the option is included in alternative minimum taxable income for alternative minimum tax purposes for the year of exercise. If the alternative minimum tax applies to the optionee for the year of exercise, all or a part of the excess of the amount of the optionee's alternative minimum tax liability over the optionee's "regular tax" liability for the year of exercise could generate an AMT tax credit that may be applied in one or more later tax years. The AMT credit may be applied against the optionee's tax liability in subsequent years in which the optionee's regular tax liability exceeds the optionee's AMT liability, but only to the extent of such excess.

The Company will not be allowed an income tax deduction upon the grant or exercise of an incentive stock option. Upon a disqualifying disposition by the optionee of shares acquired upon exercise of the incentive stock option, the Company will be allowed a deduction in an amount equal to the ordinary income recognized by the optionee.

Under proposed regulations issued by the Internal Revenue Service, the exercise of an option with previously acquired stock of the Company will be treated as, in effect, two separate transactions. Pursuant to Section 1036 of the Code, the first transaction will be a tax-free exchange of the previously acquired shares for the same number of new shares. The new shares will retain the basis and, except, as provided below, the holding periods of the previously acquired shares. The second transaction will be the issuance of additional new shares having a value equal to the difference between the aggregate fair market value of all of the new shares being acquired and the aggregate option exercise price for those shares. Because the exercise of an incentive stock option does not result in the recognition by the optionee of income, this issuance will also be tax-free (unless the alternative minimum tax applies, as described above). The optionee's basis in these additional shares will be zero and the optionee's holding period for these shares will commence on the date on which the shares are transferred. For purposes of the one and two-year holding period requirements which must be met for favorable incentive stock option tax treatment to apply, the holding periods of previously acquired shares are disregarded.

Non-qualified Stock Options. As in the case of incentive stock options, no income is recognized by the optionee on the grant of a non-qualified stock option. On the exercise by an optionee of a non-qualified option, generally the excess of the fair market value of the stock when the option is exercised over its cost to the optionee will be (a) taxable to the optionee as ordinary income and (b) deductible for income tax purposes by the Company. The optionee's tax basis in his stock will equal his cost for the stock plus the amount of ordinary income the optionee had to recognize with respect to the non-qualified stock option.

The Internal Revenue Service will treat the exercise of a non-qualified stock option with already owned stock of the Company as two transactions. First, there will be a tax-free exchange of the old shares for a like number of shares under Section 1036 of the Code, with such exchanged shares retaining the basis and holding period of the old shares. Second, there will be an issuance of additional new shares having a value equal to the difference between the fair market value of all new shares being acquired (including the exchanged shares and the additional new shares) and the aggregate option price for those shares. The employee will recognize ordinary income under Section 83 of the Code, in an amount equal to the fair market value of the additional new shares (i.e., the spread on the option). The additional new shares will have a basis equal to the fair market value of the additional new shares.

Accordingly, upon a subsequent disposition of stock acquired upon the exercise of a non-qualified stock option, the optionee will recognize short-term or long-term capital gain or loss, depending upon the holding

period of the stock equal to the difference between the amount realized upon disposition of the stock by the optionee and the optionee's basis in the stock.

#### COMPENSATION AND MANAGEMENT DEVELOPMENT COMMITTEE REPORT ON EXECUTIVE COMPENSATION

The Company's executive compensation program is intended to attract and retain talented executives and to motivate them to achieve the Company's business goals. The program utilizes a combination of salary, stock options and cash bonuses awarded based on the achievement of corporate performance objectives. The compensation received by its executive officers is thereby linked to the Company's performance. Within this overall policy, compensation packages for individual executive officers are intended to reflect the responsibilities of their position and past achievements with the Company, as well as the Company's performance.

The Compensation Committee is comprised of independent directors who are not employees of the Company. In its deliberations, the Committee takes into account the recommendations of appropriate Company officials. The Compensation Committee's determinations with respect to compensation for the fiscal year ended April 1, 2000 were made early in the fiscal year.

In arriving at the base salaries paid to the Company's executive officers for the year ended April 1, 2000, the Committee considered their individual contributions to the performance of the Company, their levels of responsibility, salary increases awarded in the past, the executive's experience and potential, and the level of compensation necessary, in the overall competitive environment, to retain talented individuals. All of these factors were collectively taken into account by the Committee in making a subjective assessment as to the appropriate base salary for each of the Company's executive officers, and no particular weight was assigned to any one factor.

To more closely align executive compensation with stock ownership, in May 2000, the Company's Compensation Committee approved a change in the form of payment of fiscal year 2000 and 2001 executive bonuses earned under the quarterly bonus program. As a result of the change, the executives in fiscal year 2000 were required to elect the portion of their eligible fiscal year 2000 bonus that they wish to be paid in the form of grants to purchase the Company's Common Stock in lieu of cash. The percentage of bonus to be paid in the form of grants to purchase the Company's Common Stock was required to be a minimum of fifty percent of the total eligible bonus amount. All of the executives listed on the summary compensation table elected to convert 50% of their eligible bonus to option grants to purchase the Company's Common Stock. For fiscal year 2001, the executives are required to elect that 50% of their year 2001 bonus is to be paid in the form of grants to purchase the Company's Common Stock in lieu of cash.

During the fiscal year ended April 1, 2000, the Company's quarterly bonus program was tied to the achievement by the Company and by individual business units of predetermined goals relating primarily to operating margin and balance sheet measures. Under the program, attainment of these predetermined goals resulted in payment of bonuses.

The Company's stock option program is intended to provide additional incentive to build shareholder value, to reward long-term corporate performance and to promote employee loyalty through stock ownership. Information with respect to stock options held by executive officers (including options granted during the year ended April 1, 2000) is included in the tables following this report. In determining the number of options granted to executive officers during the last fiscal year ended April 1, 2000, the Committee made a subjective assessment of the past and potential contributions of particular executive officers to the financial and operational performance of the business unit directed by the executive, and of such officer's potential for advancement. The Committee, in arriving at the number of options to be granted to particular executive officers, was aware of whether or not such officers had been granted options in the past. The vesting of options granted is not dependent upon the achievement of predetermined performance goals. Nevertheless, the amount realized by a recipient from an option grant will depend on the future appreciation in the price of the Company's Common Stock.

In 1993 the Internal Revenue Code was amended to limit the deduction a public company is permitted for compensation paid in 1994 and thereafter to the chief executive officer and to the four most highly compensated executive officers, other than the chief executive officer. Generally, amounts paid in excess of \$1 million to a covered executive, other than performance-based compensation, cannot be deducted. In order to qualify as performance-based compensation under the new tax law, certain requirements must be met, including approval of the performance measures by the stockholders. In its deliberations, the Committee considers ways to maximize deductibility of executive compensation, but nonetheless retains the discretion to compensate executive officers at levels the Committee considers commensurate with their responsibilities and achievements.

#### Compensation of Chief Executive Officer

In accordance with the approval of the Compensation and Management Development Committee in May 1999, Mr. Peterson received a salary for the

fiscal year ended April 1, 2000 of \$430,744. The Committee did not grant Mr. Peterson any new options to purchase shares of the Company's Common Stock during the fiscal year ended April 1, 2000. Included in the options granted to Mr. Peterson during fiscal years ended March 28, 1998 and April 3, 1999, were options to purchase 300,000 shares of the Company's Common Stock. These 300,000 options were granted as a two-year grant on Mr. Peterson's appointment to Chief Executive Officer. The options vest beginning one year from the grant date at a rate of 25% per year over the four years following the grant (except in the case of death, termination or retirement). Years 2, 3 and 4 of the vesting schedule can be accelerated effective one year from the grant date based upon the attainment of certain stock fair market values as follows: 25% upon stock value appreciation to \$21.00 per share, 25% upon stock value appreciation to \$26.00 per share and 25% upon stock value appreciation to \$31.00 per share.

At the May 2000 Compensation Committee meeting, Mr. Peterson was granted options to purchase up to 280,000 shares of the Company's Common Stock. This grant is a two-year grant in anticipation of Company performance during both fiscal years 2001 and 2002 vesting 50% on March 31, 2001 and 50% on March 31, 2002.

Mr. Peterson was not part of a bonus program during the fiscal year ended April 1, 2000. However, in recognition of the Company's performance during the fiscal year ended April 1, 2000, the Compensation and Management Development Committee in May 2000 awarded Mr. Peterson a cash bonus of \$172,990.

Compensation and Management  
Development Committee

Sir Stuart Burgess  
Donna C.E. Williamson  
Benjamin L. Holmes  
N. Colin Lind  
Ronald G. Gelbman

COMPENSATION AND MANAGEMENT DEVELOPMENT COMMITTEE  
INTERLOCKS AND INSIDER PARTICIPATION

During the fiscal year ended April 1, 2000 the members of the Compensation Committee were Sir Stuart Burgess, Donna C.E. Williamson, Benjamin L. Holmes, N. Colin Lind, Jerry E. Robertson (until November 1, 1999) and effective January 25, 2000, Ronald G. Gelbman. No member of the Compensation Committee was an officer or employee of the Company or any of its subsidiaries during fiscal year 2000.

EXECUTIVE COMPENSATION

The following table sets forth all compensation awarded to, or earned by or paid to the Company's Chief Executive Officer and each of the Company's executive officers (other than the Chief Executive Officer) whose total annual salary and bonus exceeded \$100,000 for all services rendered as executive officers to the Company and its subsidiaries for the Company's fiscal years ended April 1, 2000, April 3, 1999 and March 28, 1998.

Summary Compensation Table

Name and Principal Position	Year	Annual Compensation			Long-Term Compensation Awards	All Other compensation(2)
		Salary(1)	Bonus(1)	Other Annual Compensation	Stock Options	
James L. Peterson President & CEO	2000	\$430,744(4)	\$172,990	\$504,091(3)(4)(5)	0	
	1999	\$394,658(4)	\$150,000	\$176,642(3)(4)(5)	91,574	
	1998	\$369,945(4)	-	\$ 91,085(3)(4)(5)	330,000	
Mr. Ronald J. Ryan CFO & Sr. Vice President, Finance	2000	\$264,370	\$ 77,031	\$ 9,571(3)	46,508	\$6,000
	1999	\$249,995	\$ 81,775	\$ 9,332(3)	50,000	
Michael P. Mathews President, Blood Bank Division	2000	\$244,431	\$ 13,644	\$294,470(3)(5)	18,217	\$6,000
	1999	\$237,776	\$ 40,311	\$173,479(3)(5)	49,000	\$6,000
	1998	\$220,080	-	\$230,293(5)	69,177	\$3,000
Bruno Deglaire President, European and Asian Field Operations	2000	\$273,712	\$ 8,274	\$ 22,350(3)(4)(5)	35,982	
	1999	\$267,582	\$ 80,231	\$ 28,253(3)(4)(5)	52,500	
	1998	\$263,362	\$ 30,476	\$ 28,461(3)(4)(5)	46,640	
Peter A. Tomasulo, M.D. President, Surgical Division	2000	\$258,381	\$ 15,201	\$ 82,422(3)(4)(5)	41,581	

Salary and bonus amounts are presented in the year earned. The payment of such amounts may have occurred in other years.

Includes discretionary contributions paid by the Company with respect to the Company's 401(k) Plan: i) in 1998: for Mr. Mathews \$2,000. No discretionary contributions were made by the Company with respect to the Savings Plus Plan in 2000 or 1999. Also includes matching contributions by the Company under its 401(k) Plan: (i) in 2000: for Mr. Mathews \$6000, for Mr. Ryan \$6000, (ii) in 1999: for Mr. Mathews \$6,000, (iii) in 1998: for Mr. Mathews \$1,000.

Includes the following amounts paid by the Company with respect to vacation hours: (i) accrued in 2000 but not used: for Mr. Mathews \$4,727, (ii) accrued in 1999 but not used: for Mr. Mathews \$9,267. Additionally, includes the following amounts paid by the Company with respect to company-owned vehicles or auto allowances: (i) in 2000: for Mr. Peterson \$23,673, for Mr. Deglaire \$16,791, for Mr. Mathews \$15,284, for Mr. Ryan \$6,850, for Mr. Tomasulo \$15,858 (ii) in 1999: for Mr. Peterson \$23,765, for Mr. Deglaire \$18,025, for Mr. Ryan \$5,282, (iii) in 1998: for Mr. Peterson \$17,741, for Mr. Deglaire \$17,741.

All amounts are translated into U.S. dollars using average monthly exchange rates.

Includes the following amounts for additional payments relating to living abroad: (i) in 2000: for Mr. Mathews \$268,581, for Mr. Tomasulo \$51,569 (ii) in 1999: for Mr. Mathews \$162,855 (iii) in 1998: for Mr. Peterson \$64,352, for Mr. Mathews \$228,936. Includes the following amounts for housing allowances for Mr. Peterson: in 2000 \$65,198, in 1999 \$104,938. Includes the following amounts for travel allowances (i) in 2000: for Mr. Peterson \$59,642, Mr. Deglaire \$2,602, (ii) in 1999: for Mr. Peterson \$2,018, for Mr. Deglaire 8,384 (iii) in 1998: for Mr. Deglaire \$8,252. Includes \$337,235 in tax equalization payments for Mr. Peterson in 2000. Includes \$33,333 in one time relocation expenses for Mr. Peterson in 1999.

The Directors of the Company who are not employees of the Company receive an annual cash fee of \$10,000. Ronald G. Gelbman however, as he was elected to the Board of Directors effective January 25, 2000, received a cash fee of \$2,500 during the fiscal year ended April 1, 2000. In addition to this director fee, each outside director, except Ronald G. Gelbman and Sir Stuart Burgess, was granted, during the last fiscal year, an option to purchase up to 9,000 shares of Common Stock of the Company. Mr. Gelbman was granted, during the last fiscal year, an option to purchase up to 6,000 shares of Common Stock of the Company. Sir Stuart Burgess, as compensation for his additional duties performed as Chairman of the Board, was paid a base fee of \$45,000 which he elected to receive in the form of \$20,000 in cash and the remainder in options to purchase 6,732 shares of the Company's common stock. Sir Stuart was also granted additional options to purchase up to 30,000 shares of Common Stock of the Company and he received \$1,000 per day for each day devoted to Chairman responsibilities (or a total of \$58,000 for the fiscal year ended April 1, 2000.)

#### Option Grants in Fiscal Year Ended April 1, 2000

The following table provides information on option grants to the executive officers of the Company listed in the Summary Compensation Table above during the fiscal year ended April 1, 2000. Pursuant to applicable regulations of the Securities and Exchange Commission, the table also sets forth the hypothetical value which might be realized with respect to such options based on assumed rates of stock appreciation of 5% and 10% compounded annually from the date of grant to the end of the option term.

	Individual Grants				Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term(3)	
	Number of Securities Underlying Options Granted	Percentage of Total Options Granted to Employees in the Fiscal Year 1999	Exercise or Base Price Per Share	Expiration Date	5%	10%
James L. Peterson	-	-	-	-	-	-
Michael P. Mathews	18,217(1)	1.68	\$15.875	5/03/09	\$181,873.10	\$460,902.15
Bruno Deglaire	20,982(1)	1.94	\$15.875	5/03/09	\$209,478.04	\$530,858.48
	15,000(2)	1.38	\$15.875	5/03/09	\$149,755.53	\$379,509.92
Peter A. Tomasulo, M.D.	6,581(1)	0.61	\$15.875	5/03/09	\$ 65,702.74	\$166,503.65
	10,000(2)	0.92	\$15.875	5/03/09	\$ 99,837.02	\$253,006.62
	25,000(2)	2.31	\$17.750	10/27/09	\$279,071.99	\$707,223.22
Ronald J. Ryan	26,508(1)	2.45	\$15.875	5/03/09	\$264,647.98	\$670,669.94
	20,000(2)	1.84	\$15.875	5/03/09	\$199,674.04	\$506,013.23

Options are exercisable upon completion of one full year of employment following the grant date (except in the case of death, termination or retirement) and vest at the rate of 50% per year over



the two years following the grant date.  
Options are exercisable upon completion of one full year of employment following the grant date (except in the case of death, termination or retirement) and vest at the rate of 25% per year over the four years following the grant date.

These values are based on assumed rates of appreciation only. Actual gains, if any, on shares acquired on option exercises are dependent on the future performance of the Company's Common Stock. There can be no assurance that the values reflected in this table will be achieved. On May 15, 2000 the closing price of the Company's Common Stock on the New York Stock Exchange was 20 15/16.

#### Aggregated Option Exercises in Fiscal Year Ended April 1, 2000 and Option Values at March 31, 2000

The following table provides information on the value of unexercised options held by the executive officers listed in the Summary Compensation Table above at April 1, 2000.

	Shares Acquired on Exercise	Value Realized	Number of Unexercised Options at April 1, 2000		Value of Unexercised Options at March 31, 2000(1)	
			Exercisable	Unexercisable	Exercisable	Unexercisable
James L. Peterson	0	\$0	485,855	114,145	\$2,675,739.43	\$708,159.91
Michael P. Mathews	0	\$0	144,567	80,250	\$ 705,350.47	\$420,489.73
Bruno Deglaire	0	\$0	104,591	87,358	\$ 561,884.36	\$489,023.95
Peter A. Tomasulo, M.D.	0	\$0	27,332	76,583	\$ 133,470.90	\$410,547.73
Ronald J. Ryan	0	\$0	37,500	109,008	\$ 220,527.05	\$647,821.68

Value of unexercised stock options represents difference between the exercise prices of the stock options and the closing price of the Company's Common Stock on the New York Stock Exchange on March 31, 2000.

#### COMPARATIVE PERFORMANCE GRAPH

The following graph compares the cumulative total return for the five year period commencing March 31, 1995 through March 31, 2000 among the Company, the S&P 500 Index and the S&P Medical Products and Supplies Index. The graph assumes one hundred dollars invested on March 31, 1995 in the Company's Common Stock, the S&P 500 index and the S&P Medical Products and Supplies Index and also assumes reinvestment of dividends.

	3/31/95	3/31/96	3/31/97	3/31/98	3/31/99	3/31/00
Haemonetics Corporation	\$100	115	122	124	108	155
S&P 500	\$100	132	158	234	278	327
S&P Medical Products & Supplies	\$100	149	163	236	310	323

#### STOCKHOLDER PROPOSALS

Any proposal submitted for inclusion in the Company's Proxy Statement and form of proxy relating to the 2001 Annual Meeting of Stockholders must be received at the Company's principal executive offices in Braintree, Massachusetts on or before February 19, 2001. In accordance with the provisions of Rule 14a-4(c) promulgated under the Securities Exchange Act of 1934, if the Company does not receive notice of a shareholder proposal to be raised at its 2001 Annual Meeting on or before May 4, 2001, then in such event, the management proxies shall be allowed to use their discretionary voting authority when the proposal is raised at the 2001 Annual Meeting.

#### OTHER MATTERS

Management knows of no matters which may properly be and are likely to be brought before the meeting other than the matters discussed herein. However, if any other matters properly come before the meeting, the persons named in the enclosed proxy will vote in accordance with their best judgment.

#### VOTING PROXIES

The Board of Directors recommends an affirmative vote on all proposals specified. Proxies will be voted as specified. If signed proxies are returned without specifying an affirmative or negative vote on any proposal, the shares represented by such proxies will be voted in favor of the Board of Directors' recommendations.

By Order of the Board of Directors

/s/ Alicia R. Lopez

-----

Braintree, Massachusetts  
November 13, 2000

Alicia R. Lopez  
Clerk

DETACH HERE

PROXY

HAEMONETICS CORPORATION

Special Meeting of Stockholders  
December 14, 2000

The undersigned hereby appoints Sir Stuart Burgess and James L. Peterson or any one of them, with full power of substitution, attorneys and proxies to represent the undersigned at the Special Meeting of Stockholders of Haemonetics Corporation to be held Thursday, December 14, 2000 at the offices of Haemonetics Corporation, 400 Wood Road, Braintree, Massachusetts and at any adjournment or adjournments thereof, to vote in the name and place of the undersigned with all the power which the undersigned would possess if personally present, all of the stock of Haemonetics Corporation standing in the name of the undersigned, upon such business as may properly come before the meeting, including the following as set forth on the reverse side.

PLEASE DATE AND SIGN THIS PROXY IN THE SPACE PROVIDED ON THE REVERSE SIDE AND RETURN IT IN THE ENCLOSED ENVELOPE WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING IN PERSON.

SEE REVERSE SIDE      CONTINUED AND TO BE SIGNED ON REVERSE SIDE      SEE REVERSE SIDE

HAEMONETICS CORPORATION

Dear Shareholder:

There is one item to be considered at the Special Meeting on December 14, 2000 that requires your vote.

Your vote counts, and you are strongly encouraged to exercise your right to vote.

Please mark the boxes on the proxy card to indicate how your shares shall be voted. Then, please sign the card and return it in the enclosed, paid envelope.

Your vote must be received by the meeting date of December 14, 2000 to be considered.

Thank you for your prompt attention to this matter.

Sincerely,

/s/ Alicia R. Lopez

Haemonetics Corporation

DETACH HERE

[X] Please mark votes  
as in this example.

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. ANY PROXY HERETOFORE GIVEN BY THE UNDERSIGNED WITH RESPECT TO SUCH STOCK IS HEREBY REVOKED. THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR ITEM 1.

1. To approve the Haemonetics Corporation 2000 Long-Term Incentive Plan.

FOR            AGAINST            ABSTAIN  
[ ]            [ ]            [ ]

2. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting.

MARK HERE FOR ADDRESS CHANGE AND NOTE AT LEFT      [ ]

Please sign exactly as your name(s) appear(s) on the Proxy. When shares are held by joint tenants, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. If a corporation, please sign in full corporate name by President or other authorized officer. If a partnership, please sign in partnership name by authorized person.

Signature:	Date:	Signature:	Date:
- - - - -	- - - - -	- - - - -	- - - - -